Assignee
ACCELERON PHARMA INC
US·135 granted patents·139 pending applications·1,546 citations·filing 2005–2025
Top patents by PatentIndex Score
274 records- 0199US10973880B2Compositions and methods for treating pulmonary hypertensionACCELERON PHARMA INC·Filed 2020·Granted Apr 13, 2021·7 cites·29 claims
- 0299US8343933B2Variants derived from ActRIIB and uses thereforACCELERON PHARMA INC·Filed 2010·Granted Jan 1, 2013·91 cites·25 claims
- 0399US7842663B2Variants derived from ActRIIB and uses thereforACCELERON PHARMA INC·Filed 2008·Granted Nov 30, 2010·135 cites·15 claims
- 0499US7709605B2ActRII receptor polypeptides, methods and compositionsACCELERON PHARMA INC·Filed 2005·Granted May 4, 2010·145 cites·29 claims
- 0599US7612041B2Isolated activin-binding ActRIIa polypeptide comprising the SEQ ID NO: 7 and uses for promoting bone growthACCELERON PHARMA INC·Filed 2006·Granted Nov 3, 2009·132 cites·30 claims
- 0698US11219666B2Compositions and methods for treating pulmonary hypertensionACCELERON PHARMA INC·Filed 2020·Granted Jan 11, 2022·5 cites·29 claims
- 0798US11065303B2Compositions and methods for treating pulmonary hypertensionACCELERON PHARMA INC·Filed 2020·Granted Jul 20, 2021·6 cites·26 claims
- 0898US10946067B2Compositions and methods for treating pulmonary hypertensionACCELERON PHARMA INC·Filed 2020·Granted Mar 16, 2021·6 cites·30 claims
- 0998US10889626B2Combined use of GDF traps and erythropoietin receptor activators to increase red blood cell levelsACCELERON PHARMA INC·Filed 2020·Granted Jan 12, 2021·4 cites·25 claims
- 1098US10829532B2Combined use of gdf traps and erythropoietin receptor activators to increase red blood cell levelsACCELERON PHARMA INC·Filed 2020·Granted Nov 10, 2020·4 cites·24 claims
- 1198US10722558B2Compositions and methods for treating pulmonary hypertensionACCELERON PHARMA INC·Filed 2017·Granted Jul 28, 2020·15 cites·42 claims
- 1298US10695405B2Compositions and methods for treating pulmonary hypertensionACCELERON PHARMA INC·Filed 2018·Granted Jun 30, 2020·13 cites·17 claims
- 1398US8361957B2Isolated GDF trap polypeptideACCELERON PHARMA INC·Filed 2011·Granted Jan 29, 2013·42 cites·14 claims
- 1498US7988973B2Activin-ActRII antagonists and uses for increasing red blood cell levelsACCELERON PHARMA INC·Filed 2007·Granted Aug 2, 2011·108 cites·37 claims
- 1598US7951771B2Activin-ActRIIa antagonists and uses for promoting bone growthACCELERON PHARMA INC·Filed 2008·Granted May 31, 2011·56 cites·17 claims
- 1697US10487144B2Methods for treating ulcers in a hemoglobinopathy anemia with a soluble actRIIB polypeptideACCELERON PHARMA INC·Filed 2017·Granted Nov 26, 2019·16 cites·21 claims
- 1797US10377996B2Methods of identifying ActRIIB variantsACCELERON PHARMA INC·Filed 2016·Granted Aug 13, 2019·24 cites·11 claims
- 1897US10259861B2Variants derived from ActRIIB and uses thereforACCELERON PHARMA INC·Filed 2016·Granted Apr 16, 2019·22 cites·11 claims
- 1997US10131700B2Methods for treating refractory anemia with ringed sideroblastsACCELERON PHARMA INC·Filed 2017·Granted Nov 20, 2018·20 cites·25 claims
- 2097US9932379B2Isolated nucleotide sequences encoding GDF trapsACCELERON PHARMA INC·Filed 2016·Granted Apr 3, 2018·19 cites·12 claims
- 2197US9850298B2Methods for treating ulcers in thalassemia syndrome with an ActRIIB polypeptideACCELERON PHARMA INC·Filed 2015·Granted Dec 26, 2017·23 cites·26 claims
- 2297US9745559B2Method for decreasing the body fat content in a subject by administering an ActRIIB proteinACCELERON PHARMA INC·Filed 2015·Granted Aug 29, 2017·22 cites·20 claims
- 2397US9353356B2Activin-actriia antagonists for treating a follicle-stimulating horomone-secreting pituitary tumorACCELERON PHARMA INC·Filed 2013·Granted May 31, 2016·36 cites·45 claims
- 2497US8367611B2Activin-actriia antagonists for inhibiting germ cell maturationACCELERON PHARMA INC·Filed 2011·Granted Feb 5, 2013·35 cites·19 claims
- 2597US8007809B2Activin-actrii antagonists and uses for increasing red blood cell levelsACCELERON PHARMA INC·Filed 2008·Granted Aug 30, 2011·83 cites·37 claims
- 2697US7960343B2Activin-ActRIIa antagonists and uses for decreasing or inhibiting FSH secretionACCELERON PHARMA INC·Filed 2008·Granted Jun 14, 2011·48 cites·40 claims
- 2796US11622992B2Compositions and methods for treating pulmonary hypertensionACCELERON PHARMA INC·Filed 2020·Granted Apr 11, 2023·3 cites·20 claims
- 2896US10689427B2Combined use of GDF traps and erythropoietin receptor activators to increase red blood cell levelsACCELERON PHARMA INC·Filed 2018·Granted Jun 23, 2020·7 cites·17 claims
- 2996US10550170B2Methods for treating vascular eye disorders with actrii antagonistsACCELERON PHARMA INC·Filed 2016·Granted Feb 4, 2020·21 cites·44 claims
- 3096US10358633B2Method for producing an ActRIIB-Fc fusion polypeptideACCELERON PHARMA INC·Filed 2017·Granted Jul 23, 2019·15 cites·7 claims
- 3196US9809637B2Transforming growth factor beta receptor II fusion polypeptidesACCELERON PHARMA INC·Filed 2016·Granted Nov 7, 2017·19 cites·9 claims
- 3296US9617319B2ActRIIB proteins and variants and uses therefore relating to utrophin induction for muscular dystrophy therapyACCELERON PHARMA INC·Filed 2014·Granted Apr 11, 2017·21 cites·24 claims
- 3396US9505813B2Use of GDF traps to treat anemiaACCELERON PHARMA INC·Filed 2013·Granted Nov 29, 2016·20 cites·63 claims
- 3496US9439945B2Isolated nucleotide sequences encoding GDF trapsACCELERON PHARMA INC·Filed 2014·Granted Sep 13, 2016·18 cites·15 claims
- 3596US9399669B2Variants derived from ActRIIBACCELERON PHARMA INC·Filed 2012·Granted Jul 26, 2016·27 cites·29 claims
- 3696US9181533B2Truncated ACTRIIB-FC fusion proteinACCELERON PHARMA INC·Filed 2012·Granted Nov 10, 2015·26 cites·19 claims
- 3796US9163075B2Isolated polynucleotide that encodes an ActRIIa-Fc fusion polypeptideACCELERON PHARMA INC·Filed 2013·Granted Oct 20, 2015·20 cites·33 claims
- 3894US10189882B2Methods for treating myelodysplastic syndromes and sideroblastic anemiasACCELERON PHARMA INC·Filed 2015·Granted Jan 29, 2019·21 cites·25 claims
- 3994US9919030B2Follistatin fusion proteins and uses thereofACCELERON PHARMA INC·Filed 2015·Granted Mar 20, 2018·5 cites·23 claims
- 4093US11028145B2ALK7:actriib heteromultimers and uses thereofACCELERON PHARMA INC·Filed 2019·Granted Jun 8, 2021·4 cites·23 claims
- 4193US10358476B2Single arm type I and type II receptor fusion proteins and uses thereofACCELERON PHARMA INC·Filed 2016·Granted Jul 23, 2019·12 cites·16 claims
- 4293US10227393B2TGF-beta superfamily type I and type II receptor heteromultimers and uses thereofACCELERON PHARMA INC·Filed 2016·Granted Mar 12, 2019·9 cites·27 claims
- 4393US7807631B2Methods of promoting growth of muscle tissue using ALK7ACCELERON PHARMA INC·Filed 2008·Granted Oct 5, 2010·15 cites·67 claims
- 4492US10093707B2Antagonists of activin-ActRIIa and uses for increasing red blood cell levelsACCELERON PHARMA INC·Filed 2014·Granted Oct 9, 2018·16 cites·6 claims
- 4592US10071135B2Method of identifying an agent that promotes bone growth or increases bone densityACCELERON PHARMA INC·Filed 2015·Granted Sep 11, 2018·6 cites·12 claims
- 4692US7316998B2Cerberus/Coco derivatives and uses thereofACCELERON PHARMA INC·Filed 2005·Granted Jan 8, 2008·16 cites·21 claims
- 4791US11279746B2ALK4:ActRIIB heteromultimers and uses thereofACCELERON PHARMA INC·Filed 2020·Granted Mar 22, 2022·2 cites·11 claims
- 4891US10968282B2Methods for screening compounds for increasing thermogenic adipocytesACCELERON PHARMA INC·Filed 2019·Granted Apr 6, 2021·2 cites·15 claims
- 4991US10738098B2ALK4:ActRIIB heteromultimers and uses thereofACCELERON PHARMA INC·Filed 2018·Granted Aug 11, 2020·6 cites·33 claims
- 5091US7456149B2ALK7 and myostatin inhibitors and uses thereofACCELERON PHARMA INC·Filed 2005·Granted Nov 25, 2008·11 cites·4 claims
Showing the top 50 of 274 patent records by PatentIndex Score.
Counts cover granted patents and pending applications in the PatentIndex corpus. How scoring works →